Welcome to our dedicated page for G1 Therapeutics news (Ticker: GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics stock.
G1 Therapeutics, Inc. (Nasdaq: GTHX) is a commercial-stage oncology biopharmaceutical company committed to developing next-generation therapies to improve the lives of cancer patients. The company is based in Research Triangle Park, N.C., and leverages its proprietary kinase drug discovery platform to advance a pipeline of innovative compounds. G1's flagship product, COSELA® (trilaciclib), has been approved by the FDA to decrease the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC).
In addition to COSELA, G1 Therapeutics is actively developing and evaluating trilaciclib in combination with other anti-cancer therapies. One notable project is the global, multi-center, randomized, placebo-controlled Phase 3 trial known as PRESERVE 2, which investigates trilaciclib in patients with metastatic triple-negative breast cancer (mTNBC). Preliminary results have shown promising survival benefits, indicating trilaciclib’s potential to protect bone marrow and enhance patient outcomes during cytotoxic therapy.
The company also engages in strategic partnerships to broaden its impact. For instance, G1 Therapeutics has entered agreements with companies like Pepper Bio and Jupiter Bioventures to advance the clinical development and commercialization of lerociclib, another promising CDK4/6 inhibitor. These collaborations aim to explore lerociclib's efficacy in treating various cancers, including HCC and radioprotection uses.
On the financial front, G1 Therapeutics reported revenues of $82.5 million for the full year 2023, reflecting significant growth from $51.3 million in the previous year. The company's ongoing commitment to innovation and strategic collaborations underscores its role as a key player in oncology therapeutics.
For more information, visit G1 Therapeutics and follow them on Twitter and LinkedIn.
G1 Therapeutics reported a total revenue of $6.9 million for Q1 2022, with $5.5 million from COSELA sales. The company fully transitioned to its own sales team for COSELA promotion by mid-February 2022. Initial results from ongoing Phase 2 and Phase 3 trials of trilaciclib are expected in late 2022 and 2023. Cash and cash equivalents stood at $183 million, sufficient to fund operations until 2024. However, operating expenses rose to $53.7 million, leading to a net loss of $49.2 million.
G1 Therapeutics, Inc. (GTHX), a biopharmaceutical company, announced the granting of inducement stock options for 63,500 shares and 38,000 restricted stock units (RSUs) to six new employees under the Amended and Restated 2021 Inducement Equity Incentive Plan. The stock options have a ten-year term and are exercisable at $5.39 per share, with vesting occurring over four years. The RSUs also vest over four years. This action aligns with Nasdaq Listing Rule 5635(c)(4) aimed at attracting new talent to the company.
G1 Therapeutics, Inc. (GTHX) announced a webcast and conference call for a corporate and financial update on May 4, 2022, at 8:30 a.m. ET. The event will provide insights into the company's first quarter performance. G1 Therapeutics focuses on developing therapies for cancer and is known for its product, COSELA (trilaciclib). The call can be accessed through a dedicated phone line and will also be available via a webcast on the company's website, ensuring transparency with investors.
G1 Therapeutics, a commercial-stage oncology company, announced participation in the 21st Annual Needham Virtual Healthcare Conference. CEO Jack Bailey and CMO Raj Malik will engage in a fireside chat on April 13, 2022, at 11:00 AM EDT. The event will be accessible via live webcast on their website. G1 Therapeutics focuses on developing next-generation cancer therapies, including COSELA™ (trilaciclib), with a robust clinical pipeline aimed at treating various solid tumors. For more information, visit www.g1therapeutics.com.
G1 Therapeutics (GTHX) announced the issuance of inducement stock options for 25,800 shares and 11,200 restricted stock units (RSUs) to four new employees, under the Amended and Restated 2021 Inducement Equity Incentive Plan. Each stock option is priced at $8.02, which was the closing price on the grant date, and they vest over four years. The plan allows G1 to grant equity awards to new employees as an incentive, enhancing recruitment efforts in the competitive oncology sector.
G1 Therapeutics (GTHX) presented a study at the NCCN 2022 Annual Conference revealing significant findings on myelosuppression in patients with extensive-stage small-cell lung cancer treated with chemotherapy. The retrospective analysis of 3,277 patients showed that trilaciclib reduced grade ≥ 3 myelosuppressive hematologic adverse events by 50% and all-cause hospitalizations by 74% compared to chemotherapy alone. The study highlights the potential of trilaciclib to enhance patient outcomes and decrease healthcare resource utilization.
G1 Therapeutics, Inc. (Nasdaq: GTHX) announced the grant of stock options and restricted stock units (RSUs) to four new employees under its Sales Force Inducement Equity Incentive Plan. The inducement comprises 10,800 shares of stock options and 8,800 RSUs, aimed at attracting talent. The stock options are exercisable at $10.05 per share, the closing price on the grant date, March 1, 2022. Each stock option has a ten-year term with a four-year vesting schedule. G1 Therapeutics continues to focus on developing therapies for cancer treatment, including its first product, COSELA™.
G1 Therapeutics, a commercial-stage oncology company, announced its participation in two investor conferences in March 2022. On March 8, CEO Jack Bailey will join a New Drug Launches panel at the Cowen Health Care Conference. Following this, on March 15, Bailey and CMO Raj Malik will engage in a fireside chat at the Roth Conference. Both events will be accessible via webcast on the company's events page. G1 is focused on enhancing cancer treatments with its product COSELA and has a robust pipeline for various solid tumors.
G1 Therapeutics reported total revenues of $5.8 million for Q4 2021, including $4.4 million from COSELA sales. The company completed its COSELA sales team and anticipates initial results from its Phase 3 colorectal cancer trial in early Q1 2023. G1 initiated two Phase 2 trials to explore trilaciclib’s immune mechanism. Cash reserves stood at $221.2 million, sufficient to fund operations into 2024. However, Q4 2021 net loss rose to $40 million, higher than the previous year.
G1 Therapeutics, Inc. (GTHX) will host a webcast and conference call on February 23, 2022, at 8:30 a.m. ET to discuss its corporate and financial update for Q4 and full year 2021. The call can be accessed domestically at (866) 763-6020 or internationally at (409) 216-0626 using conference code 5256086. G1 is focused on advancing therapies for cancer, notably through COSELA™ (trilaciclib), and has a diverse clinical pipeline targeting various solid tumors like colorectal and lung cancers.
FAQ
What is the current stock price of G1 Therapeutics (GTHX)?
What is the market cap of G1 Therapeutics (GTHX)?
What does G1 Therapeutics, Inc. specialize in?
What is COSELA® (trilaciclib)?
What is the PRESERVE 2 trial?
Where is G1 Therapeutics, Inc. located?
Who are G1 Therapeutics' key partners?
What recent financial achievements has G1 Therapeutics reported?
What is lerociclib?
How can I get more information about G1 Therapeutics?
What types of cancer are G1 Therapeutics’ therapies targeting?
What are G1 Therapeutics’ future goals?
